Cara Therapeutics, Inc.
- Jurisdiction
United States - LEI
549300COVOY41P0GZ881 - ISIN
US1407553072 (CARA )- Sectors
Scores
- Fair value (Benjamin Graham formula)
- N/A
- Financial strength (Piotroski F-Value)
-
3
/ 9
- Fundamental strength relative to industry (Mohanram G-Value)
-
2
/ 7
Profile
Cara Therapeutics, Inc., an early commercial-stage biopharmaceutical company, focuses on developing and commercializing chemical entities with a primary focus on pruritus and pain by selectively targeting kappa opioid receptors in the United States. Read full profile
Fundamentals
- Net revenue
€5.61M - Gross margin
61.0% - EBIT
-€17.30M - EBIT margin
-308.2% - Net income
-€17.82M - Net margin
-317.5%
Statement period: - (published )
Estimates
| Fiscal Year | Net revenue | Net income |
|---|---|---|
| N/A |
| |
| N/A |
| |
| N/A |
|
Stock price
Dividends
No dividend payouts
Analyst ratings
No analyst ratings available
Insider Transactions
No insider transactions in the last 90 days. View older insider transactions
Earnings Calls
Earnings Calls
Latest earnings call: March 4, 2024 (Q4 2023)